RAPT Therapeutics, Inc.
RAPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.86 | -3.10 | -52.25 | -8.61 |
| FCF Yield | -16.19% | -1.29% | -1.39% | -0.77% |
| EV / EBITDA | -2.77 | -60.24 | -60.47 | -117.64 |
| Quality | ||||
| ROIC | -69.15% | -82.54% | -32.69% | -36.08% |
| Gross Margin | 0.00% | 0.00% | -83.82% | 73.88% |
| Cash Conversion Ratio | 0.64 | 0.83 | 0.84 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -32.84% | – |
| Free Cash Flow Growth | 15.03% | -37.08% | -15.92% | -51.09% |
| Safety | ||||
| Net Debt / EBITDA | 1.31 | 0.32 | 0.35 | 0.35 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -131.50 | -532.03 | -437.56 | -732.57 |